According to the CRAFT causal reasoning framework (Fig. 3), small molecule blockade of Csf1R should therefore be therapeutic in epilepsy (i.e., reduce seizures) and restoration of module expression toward health by Csf1R inhibition should be predictive of therapeutic benefit. The gene discussed is CSF1R; the disease is epilepsy.